This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A look at an investigational RNAi therapeutic in development by Arrowhead Pharmaceuticals, plozasiran (ARO-APOC3), for treatment of severe hypertriglyceridemia and mixed dyslipidemia.

Ticker(s): ARWR

Who's the expert?

Institution: Trinity Health Michigan Heart

  • General non invasive cardiologist specializing in heart failure, valvular disease, coronary disease, echocardiography, pericardial disease, arrhythmias and lipid management
  • Manages 250 patients with severe hypertriglyceridemia 

Interview Goal
 Phase 2 data presented at the 2023 American Heart Association Scientific Sessions.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.